CR8105A - Anticuerpos recombinantes y fragmentos que reconocen el ganglosido n-glicolil gm3 y su uso para diagnostico y tratamiento de tumores - Google Patents
Anticuerpos recombinantes y fragmentos que reconocen el ganglosido n-glicolil gm3 y su uso para diagnostico y tratamiento de tumoresInfo
- Publication number
- CR8105A CR8105A CR8105A CR8105A CR8105A CR 8105 A CR8105 A CR 8105A CR 8105 A CR8105 A CR 8105A CR 8105 A CR8105 A CR 8105A CR 8105 A CR8105 A CR 8105A
- Authority
- CR
- Costa Rica
- Prior art keywords
- glycolyl
- glicolil
- gangloside
- diagnosis
- recombinant antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion se relaciona fundamentalmente con la produccion de inmunoglobulinas menos inmunogenicas por la via de la ingenieria genetica, y mas especificamente con un anticuerpo monoclonal que reconoce antigenos que contienen el gangliosido N-glicolil GM3 y no otros gangliosidos del tipo N- glicolil o N-acetil, ni a los glicolýpidos sulfatados. Mas especificamente la presente invencion se relaciona con las secuencias peptidicas que codifican un anticuerpo monoclonal recombinante contra el gangliosido n-glicolil GM3, o fragmentos derivados del mismo y composiciones faramaceuticas conteniendo dicho anticuerpo o sus fragmentos y su uso tanto diagnostico o terapeutico en cancer de mama y melanoma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20030092A CU23403A1 (es) | 2003-04-23 | 2003-04-23 | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8105A true CR8105A (es) | 2006-05-31 |
Family
ID=40261249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8105A CR8105A (es) | 2003-04-23 | 2005-11-25 | Anticuerpos recombinantes y fragmentos que reconocen el ganglosido n-glicolil gm3 y su uso para diagnostico y tratamiento de tumores |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP1623997B1 (es) |
JP (1) | JP2006524194A (es) |
KR (1) | KR20060006937A (es) |
CN (2) | CN1809592A (es) |
AR (1) | AR044076A1 (es) |
AU (1) | AU2004232391B2 (es) |
BR (1) | BRPI0409664A (es) |
CA (1) | CA2523449C (es) |
CL (1) | CL2004000843A1 (es) |
CR (1) | CR8105A (es) |
CU (1) | CU23403A1 (es) |
EA (1) | EA008353B1 (es) |
ES (1) | ES2535813T3 (es) |
GE (1) | GEP20084476B (es) |
HK (1) | HK1183492A1 (es) |
HR (1) | HRP20050922A2 (es) |
HU (1) | HUE025266T2 (es) |
IL (1) | IL171541A (es) |
LT (1) | LT5353B (es) |
LV (1) | LV13427B (es) |
MX (1) | MXPA05011368A (es) |
MY (1) | MY144620A (es) |
NZ (1) | NZ543345A (es) |
PE (1) | PE20050422A1 (es) |
PL (1) | PL1623997T3 (es) |
RS (2) | RS20110319A3 (es) |
SI (1) | SI1623997T1 (es) |
TN (1) | TNSN05274A1 (es) |
TW (1) | TWI343923B (es) |
UY (1) | UY28289A1 (es) |
WO (1) | WO2004094477A1 (es) |
ZA (1) | ZA200509457B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69942782D1 (de) | 1998-11-27 | 2010-10-28 | Ucb Sa | Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung |
NZ544618A (en) | 2003-06-16 | 2009-02-28 | Celltech R & D Inc | Antibodies specific for sclerostin and methods for increasing bone mineralization |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
AU2011250920B2 (en) | 2010-05-14 | 2015-05-21 | Amgen Inc. | High concentration antibody formulations |
EP2681242B1 (en) | 2011-03-01 | 2018-01-24 | Amgen Inc. | Sclerostin and dkk-1 bispecific binding agents |
PE20140437A1 (es) | 2011-03-25 | 2014-04-17 | Amgen Inc | Formulaciones de anticuerpos |
HUE039786T2 (hu) | 2011-08-04 | 2019-02-28 | Amgen Inc | Csonthiány-defektusok kezelési módszere |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
EP2797953B1 (en) | 2011-12-28 | 2020-06-03 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
CU24120B1 (es) * | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
JP6770312B2 (ja) | 2012-07-05 | 2020-10-14 | ユセベ ファルマ ソシエテ アノニム | 骨疾患の治療 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
AU2016382512A1 (en) | 2015-12-30 | 2018-07-12 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
CN111566124A (zh) | 2017-10-25 | 2020-08-21 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
WO2019191534A1 (en) | 2018-03-30 | 2019-10-03 | Amgen Inc. | C-terminal antibody variants |
EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
KR102344948B1 (ko) * | 2018-09-03 | 2021-12-28 | 세종대학교산학협력단 | 인간 순수만능줄기세포에 특이적인 단일클론항체 n1-a4 |
CN113271945A (zh) | 2018-12-20 | 2021-08-17 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合 |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN110208409A (zh) * | 2019-06-05 | 2019-09-06 | 中国海洋大学 | 一种乳腺癌的生物标志物及其应用 |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
WO2021123908A1 (en) | 2019-12-20 | 2021-06-24 | Ludwig Institute For Cancer Research Ltd | Car-t cell therapy targeting ngcgm3 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU669124B2 (en) * | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
EP1759709B1 (en) * | 1994-01-25 | 2013-02-27 | Elan Pharmaceuticals Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
CA2203236A1 (en) | 1994-10-28 | 1996-05-09 | Ira Pastan | Tumor-specific antibody fragments, fusion proteins, and uses thereof |
NZ311174A (en) * | 1995-06-30 | 1999-04-29 | Mochida Pharm Co Ltd | Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody |
US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
CU22731A1 (es) * | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
-
2003
- 2003-04-23 CU CU20030092A patent/CU23403A1/es unknown
-
2004
- 2004-04-21 PE PE2004000397A patent/PE20050422A1/es not_active Application Discontinuation
- 2004-04-21 CL CL200400843A patent/CL2004000843A1/es unknown
- 2004-04-22 CN CNA2004800174578A patent/CN1809592A/zh active Pending
- 2004-04-22 MY MYPI20041468A patent/MY144620A/en unknown
- 2004-04-22 ES ES04728755.2T patent/ES2535813T3/es not_active Expired - Lifetime
- 2004-04-22 RS RS20110319A patent/RS20110319A3/en unknown
- 2004-04-22 EA EA200501653A patent/EA008353B1/ru not_active IP Right Cessation
- 2004-04-22 CN CN201210517262.6A patent/CN103012586B/zh not_active Expired - Fee Related
- 2004-04-22 TW TW093111267A patent/TWI343923B/zh not_active IP Right Cessation
- 2004-04-22 GE GEAP20049062A patent/GEP20084476B/en unknown
- 2004-04-22 RS YU20050795A patent/RS51853B/en unknown
- 2004-04-22 BR BRPI0409664-9A patent/BRPI0409664A/pt not_active Application Discontinuation
- 2004-04-22 HU HUE04728755A patent/HUE025266T2/en unknown
- 2004-04-22 SI SI200432242T patent/SI1623997T1/sl unknown
- 2004-04-22 KR KR1020057020182A patent/KR20060006937A/ko not_active Application Discontinuation
- 2004-04-22 CA CA2523449A patent/CA2523449C/en not_active Expired - Lifetime
- 2004-04-22 AU AU2004232391A patent/AU2004232391B2/en not_active Ceased
- 2004-04-22 WO PCT/CU2004/000006 patent/WO2004094477A1/es active IP Right Grant
- 2004-04-22 MX MXPA05011368A patent/MXPA05011368A/es active IP Right Grant
- 2004-04-22 NZ NZ543345A patent/NZ543345A/en not_active IP Right Cessation
- 2004-04-22 PL PL04728755T patent/PL1623997T3/pl unknown
- 2004-04-22 JP JP2006504218A patent/JP2006524194A/ja active Pending
- 2004-04-22 EP EP04728755.2A patent/EP1623997B1/en not_active Expired - Lifetime
- 2004-04-23 AR ARP040101389A patent/AR044076A1/es active IP Right Grant
- 2004-04-23 UY UY28289A patent/UY28289A1/es not_active Application Discontinuation
-
2005
- 2005-10-21 HR HR20050922A patent/HRP20050922A2/xx not_active Application Discontinuation
- 2005-10-21 TN TNP2005000274A patent/TNSN05274A1/en unknown
- 2005-10-23 IL IL171541A patent/IL171541A/en active IP Right Grant
- 2005-11-21 LT LT2005101A patent/LT5353B/lt not_active IP Right Cessation
- 2005-11-22 LV LVP-05-152A patent/LV13427B/en unknown
- 2005-11-22 ZA ZA200509457A patent/ZA200509457B/en unknown
- 2005-11-25 CR CR8105A patent/CR8105A/es not_active Application Discontinuation
-
2013
- 2013-09-19 HK HK13110760.2A patent/HK1183492A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8105A (es) | Anticuerpos recombinantes y fragmentos que reconocen el ganglosido n-glicolil gm3 y su uso para diagnostico y tratamiento de tumores | |
PE20200337A1 (es) | Receptores de celulas t novedosos, e inmunoterapia usando los mismos | |
PE20191493A1 (es) | Receptores de linfocitos t e inmuno terapias basadas en el uso de los mismos contra canceres positivos para prame | |
MX2020004741A (es) | Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos. | |
PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
PE20081625A1 (es) | Proteinas de union al antigeno del receptor a de la il-17 | |
BR112021018694A2 (pt) | Vesículas extracelulares para distribuição de vacina | |
AR076668A1 (es) | Anticuerpos especificos para dkk-1 y sus usos | |
PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
AR050036A1 (es) | Anticuerpos anti - igf- ir y sus usos | |
UY32560A (es) | Inmunoconjugados de antimesotelina y usos de los mismos | |
AR108663A1 (es) | ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS | |
AR062895A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
CO6280409A2 (es) | Anticuerpos antimesotelina y usos de los mismos | |
AR071304A1 (es) | Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer | |
CR11374A (es) | Proteinas humanas de union a antigenos del gm-csf | |
ECSP12011698A (es) | Anticuerpos cea | |
AR067666A1 (es) | Proteinas de union al antigeno del receptor de il-18 | |
AR066987A1 (es) | Anticuerpo monoclonal contra proteina beta-amiloide | |
PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
BR112022011339A2 (pt) | Composições de células terapêuticas e métodos para fabricação e usos das mesmas | |
AR077972A1 (es) | Anticuerpos contra cdcp1 destinados al tratamiento del cancer | |
NZ750948A (en) | Anti-gp73 antibodies and immunoconjugates | |
ECSP056112A (es) | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores | |
CO2019002550A2 (es) | Anticuerpos anti-gm-csf y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |